{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T01:37:22Z","timestamp":1776821842765,"version":"3.51.2"},"reference-count":47,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","cghjournal.org","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.cgh.2018.04.049","type":"journal-article","created":{"date-parts":[[2018,4,30]],"date-time":"2018-04-30T14:58:08Z","timestamp":1525100288000},"page":"1488-1494.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Development and Validation of a Test to Identify Drugs That Cause Idiosyncratic Drug-Induced Liver Injury"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8387-1319","authenticated-orcid":false,"given":"Andreas","family":"Benesic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Rotter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Dragoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Luise","family":"Buchholtz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander L.","family":"Gerbes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2018.04.049_bib1","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.cld.2013.07.001","article-title":"Drug-induced acute liver failure","volume":"17","author":"Lee","year":"2013","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.cgh.2018.04.049_bib2","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1056\/NEJMra1208937","article-title":"Acute liver failure","volume":"369","author":"Bernal","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2018.04.049_bib3","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1055\/s-0034-1375962","article-title":"Drug-induced liver injury and drug development: industry perspective","volume":"34","author":"Regev","year":"2014","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.cgh.2018.04.049_bib4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/ijms17050714","article-title":"Case characterization. Clinical features and risk factors in drug-induced liver injury","volume":"17","author":"Ortega-Alonso","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cgh.2018.04.049_bib5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1055\/s-0034-1375954","article-title":"Genetic basis of drug-induced liver injury: present and future","volume":"34","author":"Urban","year":"2014","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.cgh.2018.04.049_bib6","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.cld.2013.07.002","article-title":"Mechanisms of drug induced liver injury","volume":"17","author":"Yuan","year":"2013","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.cgh.2018.04.049_bib7","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jhep.2015.04.016","article-title":"Drug-induced liver injury: interactions between drug properties and host factors","volume":"63","author":"Chen","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2018.04.049_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejim.2015.12.017","article-title":"Adverse drug reactions and organ damage: the liver","volume":"28","author":"Licata","year":"2016","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.cgh.2018.04.049_bib9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1517\/14740338.2013.828032","article-title":"Idiosyncratic drug-induced liver injury: an update on the 2007 overview","volume":"13","author":"Hussaini","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.cgh.2018.04.049_bib10","doi-asserted-by":"crossref","first-page":"9737920","DOI":"10.1155\/2016\/9737920","article-title":"Key challenges and opportunities associated with the use of in\u00a0vitro models to detect human DILI: integrated risk assessment and mitigation plans","volume":"2016","author":"Atienzar","year":"2016","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.cgh.2018.04.049_bib11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00204-016-1874-9","article-title":"Current limitations and future opportunities for prediction of DILI from in\u00a0vitro","volume":"91","author":"Funk","year":"2017","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.cgh.2018.04.049_bib12","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/hep.28886","article-title":"Stem cell-derived models to improve mechanistic understanding and prediction of human drug-induced liver injury","volume":"65","author":"Goldring","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2018.04.049_bib13","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1517\/14740338.2016.1160057","article-title":"Recent advances in biomarkers and therapeutic interventions for hepatic drug safety - false dawn or new horizon?","volume":"15","author":"Clarke","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.cgh.2018.04.049_bib14","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1055\/s-0035-1567829","article-title":"Genome-wide association studies in drug-induced liver injury: step change in understanding the pathogenesis","volume":"35","author":"Aithal","year":"2015","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.cgh.2018.04.049_bib15","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3389\/fphar.2016.00267","article-title":"Biomarkers in DILI: one more step forward","volume":"7","author":"Robles-D\u00edaz","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cgh.2018.04.049_bib16","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/ilar\/ilw025","article-title":"The promise of new technologies to reduce, refine, or replace animal use while reducing risks of drug induced liver injury in pharmaceutical development","volume":"57","author":"Sistare","year":"2016","journal-title":"ILAR J"},{"key":"10.1016\/j.cgh.2018.04.049_bib17","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1055\/s-0034-1375955","article-title":"Clinical features, diagnosis, and natural history of drug-induced liver injury","volume":"34","author":"Hayashi","year":"2014","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.cgh.2018.04.049_bib18","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/j.cgh.2015.06.017","article-title":"The art and science of diagnosing and managing drug-induced liver injury in 2015 and beyond","volume":"13","author":"Lewis","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2018.04.049_bib19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/1547691X.2016.1254305","article-title":"Development of a modified lymphocyte transformation test for diagnosing drug-induced liver injury associated with an adaptive immune response","volume":"14","author":"Whritenour","year":"2017","journal-title":"J\u00a0Immunotoxicol"},{"key":"10.1016\/j.cgh.2018.04.049_bib20","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/ajg.2014.131","article-title":"ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury","volume":"109","author":"Chalasani","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2018.04.049_bib21","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1136\/gut.2008.163675","article-title":"Diagnosis, management and prevention of drug-induced liver injury","volume":"58","author":"Verma","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2018.04.049_bib22","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/hep.28323","article-title":"Categorization of drugs implicated in causing liver injury: critical assessment based on published case reports","volume":"63","author":"Bj\u00f6rnsson","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2018.04.049_bib23","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/hep.28353","article-title":"Can rechallenge be done safely after mild or moderate drug-induced liver injury?","volume":"63","author":"Senior","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2018.04.049_bib24","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1136\/gutjnl-2016-313369","article-title":"Drug-induced liver injury: recent advances in diagnosis and risk assessment","volume":"66","author":"Kullak-Ublick","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2018.04.049_bib25","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/hep.29152","article-title":"Drug rechallenge following drug-induced liver injury","volume":"66","author":"Hunt","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2018.04.049_bib26","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1517\/14740330903397378","article-title":"Rechallenge in drug-induced liver injury: the attractive hazard","volume":"8","author":"Andrade","year":"2009","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.cgh.2018.04.049_bib27","doi-asserted-by":"crossref","first-page":"e25221","DOI":"10.1371\/journal.pone.0025221","article-title":"Correlation versus causation? Pharmacovigilance\u00a0of the analgesic flupirtine exemplifies the need for refined spontaneous ADR reporting","volume":"6","author":"Anderson","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.cgh.2018.04.049_bib28","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1111\/liv.13380","article-title":"Associations of gender and\u00a0a proxy of female menopausal status with histological features of drug-induced liver injury","volume":"37","author":"Suzuki","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2018.04.049_bib29","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jhep.2016.05.003","article-title":"Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury","volume":"65","author":"Medina-Caliz","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2018.04.049_bib30","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","article-title":"Features and\u00a0outcomes of 899 patients with drug-induced liver injury: the\u00a0DILIN prospective study","volume":"148","author":"Chalasani","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2018.04.049_bib31","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/ajg.2015.283","article-title":"Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury","volume":"110","author":"Fontana","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2018.04.049_bib32","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1007\/s40264-014-0185-4","article-title":"Causality assessment for suspected DILI during clinical phases of drug development","volume":"37","author":"Regev","year":"2014","journal-title":"Drug Saf"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2018.04.049_bib33","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1007\/s40264-014-0186-3","article-title":"Liver safety assessment in special populations (hepatitis B. C. and oncology trials)","volume":"37","author":"Kullak-Ublick","year":"2014","journal-title":"Drug Saf"},{"key":"10.1016\/j.cgh.2018.04.049_bib34","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/lt.20204","article-title":"Liver transplantation for acute liver failure from drug induced liver injury in the United States","volume":"10","author":"Russo","year":"2004","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cgh.2018.04.049_bib35","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2014.03.045","article-title":"Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality\u00a0within 6 months from onset","volume":"147","author":"Fontana","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2018.04.049_bib36","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1097\/MCG.0b013e3181c5e9cc","article-title":"The characteristics and clinical outcome of drug-induced liver injury: a single-center experience","volume":"44","author":"Idilman","year":"2010","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cgh.2018.04.049_bib37","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1055\/s-0034-1375961","article-title":"DILI and drug development: a regulatory perspective","volume":"34","author":"Avigan","year":"2014","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.cgh.2018.04.049_bib38","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1136\/gutjnl-2015-309528","article-title":"Monocyte-derived hepatocyte-like cells for causality assessment of idiosyncratic drug-induced liver injury","volume":"65","author":"Benesic","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2018.04.049_bib39","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/clpt.2011.58","article-title":"Case definition and phenotype standardization in drug-induced liver injury","volume":"89","author":"Aithal","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cgh.2018.04.049_bib40","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/hep.23696","article-title":"Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop","volume":"52","author":"Fontana","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2018.04.049_bib41","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/hep.26175","article-title":"LiverTox: a website on drug-induced liver injury","volume":"57","author":"Hoofnagle","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2018.04.049_bib42","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","article-title":"Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of International Consensus Meeting: application to drug-induced liver injuries","volume":"46","author":"Danan","year":"1993","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.cgh.2018.04.049_bib43","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/labinvest.2012.64","article-title":"Human monocyte-derived\u00a0cells with individual hepatocyte characteristics: a novel\u00a0tool for personalized in\u00a0vitro studies","volume":"92","author":"Benesic","year":"2012","journal-title":"Lab Invest"},{"key":"10.1016\/j.cgh.2018.04.049_bib44","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/FPC.0000000000000209","article-title":"HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury","volume":"26","author":"Nicoletti","year":"2016","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.cgh.2018.04.049_bib45","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.cgh.2017.05.027","article-title":"Drug-induced autoimmune hepatitis: response to corticosteroids and lack of relapse after cessation of steroids","volume":"15","author":"Bj\u00f6rnsson","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2018.04.049_bib46","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.cgh.2016.07.022","article-title":"Characterizing drug-induced liver injury with autoimmune features","volume":"14","author":"Andrade","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2018.04.049_bib47","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jhep.2018.03.033","article-title":"Herbal tea and liver injury \u2013 Tea extract or\u00a0comedication can make a difference","volume":"69","author":"Benesic","year":"2018","journal-title":"J Hepatol"}],"updated-by":[{"DOI":"10.1016\/j.cgh.2019.02.022","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000}}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356518304543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356518304543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T03:45:03Z","timestamp":1571283903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356518304543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1542356518304543"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2018.04.049","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733164436.793555308","asserted-by":"object"}]},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and Validation of a Test to Identify Drugs That Cause Idiosyncratic Drug-Induced Liver Injury","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2018.04.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the AGA Institute","name":"copyright","label":"Copyright"}]}}